658 Results

People

  1. Zelenetz
    Zelenetz
  2. Moskowitz
    Moskowitz
  3. Portlock
    Portlock
  4. Straus
    Straus
  5. Tallman
    Tallman
  6. Wolden
    Wolden
  7. Noy
    Noy
  8. Giralt
    Giralt
  9. Hamlin
    Hamlin
  10. Perales
    Perales

Groups

  1. Center for Hematologic Malignancies (658)
  2. Hematologic Malignancies, Division of (334)
  3. Hematologic Oncology, Division of (225)
  4. Lymphoma (210)
  5. Survivorship Research (192)
  6. Adult Leukemia (181)
  7. Bone Marrow Transplant (153)
  8. GSK Faculty (150)
  9. Population Sciences Research Program (116)
  10. Epidemiology and Biostatistics (115)
Refine Results
  1. "aged"
  2. "Center for Hematologic Malignancies"
Formats
  1. Journal Article (648)
  2. Research Letter (7)
  3. Conference Paper (1)
  4. Correspondence (1)
  5. Meeting Abstract (1)
Groups
  1. Center for Hematologic Malignancies (658)
  2. Hematologic Malignancies, Division of (334)
  3. Hematologic Oncology, Division of (225)
  4. Lymphoma (210)
  5. Survivorship Research (192)
  6. Adult Leukemia (181)

More Groups

People
  1. Andrew Zelenetz (81)
  2. Craig Moskowitz (57)
  3. Carol Portlock (56)
  4. David Straus (51)
  5. Sergio Giralt (50)
  6. Steven Horwitz (49)

More People

Years
  1. 2021 (10)
  2. 2020 (69)
  3. 2019 (43)
  4. 2018 (34)
  5. 2017 (21)
  6. 2016 (6)

More Years

Publications
  1. Blood (73)
  2. Journal of Clinical Oncology (65)
  3. Biology of Blood and Marrow Transplantation (43)
  4. Cancer (37)
  5. Leukemia and Lymphoma (28)
  6. British Journal of Haematology (26)

More Publications

Publishers
  1. American Society of Hematology (94)
  2. Elsevier Inc. (93)
  3. American Society of Clinical Oncology (69)
  4. Nature Publishing Group (57)
  5. Wiley Blackwell (48)
  6. John Wiley & Sons (38)

More Publishers

Results (658)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patients
    Journal Article

    Yahalom, J.; Xu, A. J.; Noy, A.; Lobaugh, S.; Chelius, M.; Chau, K.; Portlock, C.; Hajj, C.; Imber, B. S.; Straus, D. J.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Noninvasive monitoring of mantle cell lymphoma by immunoglobulin gene next-generation sequencing in a phase 2 study of sequential chemoradioimmunotherapy followed by autologous stem-cell rescue
    Journal Article

    Kumar, A.; Bantilan, K. S.; Jacob, A. P.; Park, A.; Schoninger, S. F.; Sauter, C.; Ulaner, G. A.; Casulo, C.; Faham, M.; Kong, K. A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway
    Journal Article

    Fujino, T.; Goyama, S.; Sugiura, Y.; Inoue, D.; Asada, S.; Yamasaki, S.; Matsumoto, A.; Yamaguchi, K.; Isobe, Y.; Tsuchiya, A.; more...
    Nature Communications (2021)

    Fulltext@MSK | Save
  • Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
    Journal Article

    Stahl, M.; Menghrajani, K.; Derkach, A.; Chan, A.; Xiao, W.; Glass, J.; King, A. C.; Daniyan, A. F.; Famulare, C.; Cuello, B. M.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Oncologic immunomodulatory agents in patients with cancer and COVID-19
    Journal Article

    Jee, J.; Stonestrom, A. J.; Devlin, S.; Nguyentran, T.; Wills, B.; Narendra, V.; Foote, M. B.; Lumish, M.; Vardhana, S. A.; Pastores, S. M.; more...
    Scientific Reports (2021)

    Fulltext@MSK | Save
  • Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1/2 study
    Journal Article

    Mato, A. R.; Shah, N. N.; Jurczak, W.; Cheah, C. Y.; Pagel, J. M.; Woyach, J. A.; Fakhri, B.; Eyre, T. A.; Lamanna, N.; Patel, M. R.; more...
    Lancet (2021)

    Fulltext@MSK | Save
  • Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: Results from a multicenter, randomized, phase 2/3 study
    Journal Article

    Montesinos, P.; Roboz, G. J.; Bulabois, C. E.; Subklewe, M.; Platzbecker, U.; Ofran, Y.; Papayannidis, C.; Wierzbowska, A.; Shin, H. J.; Doronin, V.; more...
    Leukemia (2021)

    Fulltext@MSK | Save
  • Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia
    Journal Article

    DiNardo, C. D.; Stein, A. S.; Stein, E. M.; Fathi, A. T.; Frankfurt, O.; Schuh, A. C.; Döhner, H.; Martinelli, G.; Patel, P. A.; Raffoux, E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Modulation of IL-6/STAT3 signaling axis in CD4(+)FOXP3(-) T cells represents a potential antitumor mechanism of azacitidine
    Journal Article

    Lamprianidou, E.; Kordella, C.; Kazachenka, A.; Zoulia, E.; Bernard, E.; Filia, A.; Laidou, S.; Garantziotis, P.; Vassilakopoulos, T. P.; Papageorgiou, S. G.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
    Journal Article

    Alsina, M.; Landgren, O.; Raje, N.; Niesvizky, R.; Bensinger, W. I.; Berdeja, J. G.; Kovacsovics, T.; Vesole, D. H.; Fang, B.; Kimball, A. S.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save